Loading...
Loading...
Browse all stories on DeepNewz
VisitFinancial impact on Regeneron after the launch of Eylea biosimilars by Q2 2025
Increase in net income • 33%
Decrease in net income • 33%
No significant change in net income • 34%
Quarterly financial reports from Regeneron
FDA Approves Biocon and Biogen Biosimilars for Regeneron's Eylea
May 20, 2024, 08:10 PM
The U.S. Food and Drug Administration (FDA) has approved two biosimilar versions of Regeneron Pharmaceuticals' blockbuster eye drug Eylea on Monday. The biosimilars, developed by Biocon Biologics and Biogen, are the first-ever biosimilar versions of Eylea to receive FDA clearance. This approval facilitates interchangeability without a doctor's prescription and does not require switching studies as part of the approvals. The launch dates for these therapies remain uncertain, but the approval marks a significant development for Regeneron as it faces increasing competition.
View original story
Profitable • 25%
Break-even • 25%
Minor losses • 25%
Significant losses • 25%
$0-100 million • 25%
$101-500 million • 25%
$501 million - $1 billion • 25%
Over $1 billion • 25%
Significant increase • 25%
Moderate increase • 25%
No significant impact • 25%
Decrease due to other factors • 25%
Regeneron • 50%
Mammoth Biosciences • 50%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
Above $2 billion • 25%
Yes • 50%
No • 50%
Amgen outperforms AstraZeneca • 33%
AstraZeneca outperforms Amgen • 33%
Both perform similarly • 34%
Increase over 20% • 25%
Increase 10-20% • 25%
Decrease 10-20% • 25%
Decrease over 20% • 25%
Becomes a top 5 vaccine company • 25%
Remains outside top 5 but improves position • 25%
No significant change in market position • 25%
Declines in market position • 25%
Biosimilars not launched • 50%
Biosimilars launched • 50%
Eylea retains majority market share • 50%
Biosimilars gain majority market share • 50%
Increase in Regeneron's stock price • 50%
Decrease in Regeneron's stock price • 50%
Equal market share between Biocon and Biogen • 34%
Biocon's biosimilar dominates • 33%
Biogen's biosimilar dominates • 33%